#Securities Class Action #Faruqi & Faruqi #PepGen Inc.

Investor Alert Regarding Potential Claims Against PepGen Inc.

Faruqi & Faruqi, LLP, a reputable national securities law firm, is actively looking into allegations that may affect investors in PepGen Inc. This investigation is particularly directed at those who may have incurred losses exceeding $50,000 between March 7, 2024, and March 3, 2025. Investors are reminded that the deadline to apply as lead plaintiff in a pending federal securities class action is August 11, 2025.

The legal team at Faruqi & Faruqi is reaching out to affected investors to discuss their rights and potential options for recourse. James (Josh) Wilson, a partner at the firm, encourages any impacted individuals to connect directly for a confidential discussion at either 877-247-4292 or 212-983-9330 (Ext. 1310).

Background on PepGen’s Allegations

The current situation stems from allegations that PepGen and its executives may have expressed misleading statements about their developmental drug PGN-EDO51, causing investors to make decisions based on incomplete and inaccurate information. The complaints suggest that claims made about PGN-EDO51’s effectiveness and the safety of related studies were significantly overstated. Furthermore, the concerns were raised regarding the CONNECT2 study connected with the United States Food and Drug Administration (FDA) and its potential risks.

For instance, on July 30, 2024, PepGen proactively announced the release of what it termed